RHHBY (OTC:RHHBY)), a pharmaceutical giant with a market capitalization of $265.76 billion, saw its price target increased by Deutsche Bank (ETR:DBKGn) from CHF250.00 to CHF265.00, while the firm ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 2,890,400 shares, an ...

4 This announcement follows the assay's CE Mark approval in Ju Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today ... for all outstanding shares of common stock of Poseida Therapeutics, Inc ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months.